Category: 70931-59-8

On September 25, 2003, Egbertson, Melissa; Langford, H. Marie; Melamed, Jeffrey Y.; Wai, John S.; Han, Wei; Perlow, Debbie S.; Zhuang, Linghang; Embrey, Mark published a patent.Reference of 1-(Bromomethyl)-4-fluoro-2-iodobenzene The title of the patent was Preparation of N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors for treatment of HIV infection/AIDS. And the patent contained the following:

Title compounds I [wherein R1 = H or F; R2 = carbamoylalkyl, carbamoyl, triazolyl or tetrazolyl, acylamino and derivatives, 2-oxopyrrolidin-1-yl and analogs, (cyclo)alkoxycarbonyl, COY; Y = azetidinyl, pyrrolidinyl, piperidinyl, morpholino; R3 = H, carbamoyl and derivatives, acylamino, carbamoyl(alkyl/methylthioxy/methyloxy/amino/alkylamino/alkenyl), (un)substituted 5- to 7-membered saturated heterocyclic ring containing 1 to 4 heteroatoms (N, O or S), (un)substituted 7- to 9-bridged azabicycloalkyl saturated ring; or their pharmaceutical acceptable salts] were prepared as HIV-integrase inhibitors for preventing and treating infection by HIV and for preventing, treating or delaying the onset of AIDS. For example, II鈥a was prepared via TEA-acylation of III鈥Cl (preparation given) with 5-(1,1-dioxo-1,2-thiazinan-2-yl)-8-hydroxy-1,6-naphthyridine-7-carboxylic acid (IV) in DMF at room temperature overnight, followed by sodium salt formation by reaction with NaOH at room temperature for 30 min. IV was prepared from 8-hydroxy-1,6-naphthyridine-7-carboxylic acid Me ester in 5 steps by NBS-bromination in CHCl3, O-tosylation in CHCl3, condensation of the bromide with 1,4-butanesultam in DMF in the presence of Cu2O/2,2′-bipyridyl at 120掳 for 4 h, deprotection of tosyl group, and base-catalyzed hydrolysis in MeOH overnight at 60掳. Selected invention compounds inhibited the strand transfer activity of HIV integrase with IC50 < 0.5 渭M. The same compounds inhibited the replication of HIV in T-lymphoid cells with IC95 < 5 渭M. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Reference of 1-(Bromomethyl)-4-fluoro-2-iodobenzene

The Article related to naphthyridinecarboxamide hiv integrase inhibitor aids composition antiviral, carboxamide naphthyridine hiv replication inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Reference of 1-(Bromomethyl)-4-fluoro-2-iodobenzene

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On September 25, 2003, Egbertson, Melissa; Langford, H. Marie; Melamed, Jeffrey Y.; Wai, John S.; Han, Wei; Perlow, Debbie S.; Zhuang, Linghang; Embrey, Mark; Young, Steven D. published a patent.Application of 70931-59-8 The title of the patent was Preparation of N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors for treatment of HIV infection/AIDS. And the patent contained the following:

Title compounds I [wherein R1 = H or F; R2 = carbamoylalkyl, carbamoyl, triazolyl or tetrazolyl, acylamino and derivatives, 2-oxopyrrolidin-1-yl and analogs, (cyclo)alkoxycarbonyl, COY; Y = azetidinyl, pyrrolidinyl, piperidinyl, morpholino; R3 = H, carbamoyl and derivatives, acylamino, carbamoyl(alkyl/methylthioxy/methyloxy/amino/alkylamino/alkenyl), (un)substituted 5- to 7-membered saturated heterocyclic ring containing 1 to 4 heteroatoms (N, O or S), (un)substituted 7- to 9-bridged azabicycloalkyl saturated ring; or their pharmaceutically acceptable salts] were prepared as HIV-integrase inhibitors for preventing and treating infection by HIV and for preventing, treating or delaying the onset of AIDS. For example, II鈥a was prepared via TEA-acylation of III鈥Cl (preparation given) with 5-(1,1-dioxo-1,2-thiazinan-2-yl)-8-hydroxy-1,6-naphthyridine-7-carboxylic acid (IV) in DMF at room temperature overnight, followed by sodium salt formation by reaction with NaOH at room temperature for 30 min. IV was prepared from 8-hydroxy-1,6-naphthyridine-7-carboxylic acid Me ester in 5 steps by NBS-bromination in CHCl3, O-tosylation in CHCl3, condensation of the bromide with 1,4-butanesultam in DMF in the presence of Cu2O/2,2′-bipyridyl at 120掳 for 4 h, deprotection of tosyl group, and base-catalyzed hydrolysis in MeOH overnight at 60掳. Selected invention compounds inhibited the strand transfer activity of HIV integrase with IC50 < 0.5 渭M. The same compounds inhibited HIV replication in T-lymphoid cells with IC95 < 5 渭M. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Application of 70931-59-8

The Article related to naphthyridinecarboxamide hiv integrase inhibitor aids composition antiviral, carboxamide naphthyridine hiv replication inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Application of 70931-59-8

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On March 5, 2021, Provencher, Philip A.; Bay, Katherine L.; Hoskin, John F.; Houk, K. N.; Yu, Jin-Quan; Sorensen, Erik J. published an article.HPLC of Formula: 70931-59-8 The title of the article was Cyclization by C(sp3)-H Arylation with a Transient Directing Group for the Diastereoselective Preparation of Indanes. And the article contained the following:

Pd(II)-catalyzed cyclative C(sp3)-H arylation of ketones with a transient directing group (TDG). Based on calculations, the oxidative addition step implicates a highly strained trigonal bipyramidal geometry around a Pd(IV) intermediate afforded by the bidentate TDG and the intramol. arylation process. As a consequence, unproductive protodeiodination outcompetes the cyclative arylation Pd(II/IV) pathway under standard conditions. The desired selectivity was achieved by prudent selection of the TDG and the Ag(I) source. The reaction was accelerated by the inclusion of stoichiometric quantities of trifluoroacetic acid, which benefits both the palladium catalysis and the attachment of the TDG for the pivotal C(sp3)-H palladation. Critically, the use of the 2-pyridone ligand improves yields significantly and enables the cyclative arylation of both Me and linear methylene C-H bonds. Mechanistically, the high energy barrier associated with the transition state of this cyclization type was sufficient to drive selective linear methylene C-H activation in the presence of a more reactive Me C-H bond. The reaction was showcased in a two-step synthesis of a substituted indane using 3-iodoanisole as the linchpin in a formal [3 + 2] annulation concept featuring two C(sp3)-H arylations. The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).HPLC of Formula: 70931-59-8

The Article related to iodophenyl alkyl ketone palladium acetate catalyst glycine cyclization diastereoselective, alkyl dihydroindenyl ethanone preparation c h activation, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Benzocyclopropenes, Benzocyclobutenes, and Indenes and other aspects.HPLC of Formula: 70931-59-8

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On May 18, 2007, Saavedra, Oscar Mario; Claridge, Stephen William; Zhan, Lijie; Raeppel, Franck; Vaisburg, Arkadii; Raeppel, Stephane; Deziel, Robert; Mannion, Michael; Zhou, Nancy Z.; Isakovic, Ljubomir published a patent.Reference of 1-(Bromomethyl)-4-fluoro-2-iodobenzene The title of the patent was Thienopyridine and thienopyrimidine derivatives and their preparation, pharmaceutical compositions, and use as inhibitors of VEGF receptor and HGF receptor signaling for treatment of proliferative diseases. And the patent contained the following:

The invention relates to the inhibition of vascular endothelial growth factor (VEGF) receptor signaling and hepatocyte growth factor (HGF) receptor signaling. The invention provides compounds of formula I and methods for inhibiting VEGF receptor signaling and HGF receptor signaling for treatment of proliferative diseases. Compounds of formula I, wherein T is (un)substituted (hetero)aryl(alkyl), cycloalkyl or heterocyclyl; W is O, S, NH, or NMe; Z is O, S, or NH; X and X1 are independently H, (un)substituted C1-6 alkyl, halo, CN, or NO2; or X and X1 together may form C3-7 cycloalkyl; R1, R2, R3, R4 are independently H, halo, trihalomethyl, CN, NO2, NH2 and derivatives, OH and derivatives, CO2H and derivatives, COH and derivatives, (un)substituted C1-4 alkoxy, (un)substituted C1-4 alkylthio, (un)substituted C1-6 alkyl, (un)substituted C2-4 alkenyl, or (un)substituted C2-6 alkynyl; R5 is H, CN, (un)substituted (CH2)2-5 (hetero)aryl, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, C2-6 alkynyl, CH2(CH2)0-4T2, (un)substituted C1-4 alkylcarbonyl, (un)saturated 3- to 7-membered carboxycyclic or heterocyclic group; where T2 is OH, OMe, OEt, NH2, NHMe, or NMe2; Q is CH2, O, S, NH, N(C1-6 alkyl), N(alkyl)aryl, NOMe, NCH2OMe, or NBn; D is C-E or N; L is N or CR where R is H, halo, CN, (un)substituted C1-6 alkyl, (un)substituted C2-4 alkenyl, or (un)substituted C2-6 alkynyl; E is E1, E2 or E3 wherein E1 is H, halo, NO2, azido, (un)substituted C1-6 alkyl, C3-10 cycloalkyl, etc.; E2 is (un)substituted alkynes; E3 is (un)substituted heterocyclyl(ene); and the pharmaceutically acceptable salts and complexes thereof are claimed in this invention. Example compound II was prepared by chlorination of thieno[3,2-b]pyridine-7-ol followed by carboxylation and the resulting lithium carboxylate was converted into the corresponding acid chloride, which reacted with dimethylamine to give compound III; compound III underwent coupling with 2-fluoro-4-nitrophenol, and the resulting 7-(2-fluoro-4-nitrophenoxy)-N,N-dimethylthienopyridinecarboamide was reduced to give the corresponding arylamine, which was reacted with phenylacetyl isocyanate to give example compound II. Addnl. 329 examples were prepared in this invention. The example compounds were tested for their in vitro HGF receptor and VEGF receptor signaling inhibition and solid tumor growth inhibition. The invention compounds showed inhibitory activity and was reported to have IC50 values less than 50 nM, ≥50 but <250 nM, ≥250 but <500 nM, ≥ 500 nM, or no activity in various assays. Example compound II showed and IC50 of >50 nM for inhibition of VEGF receptors, and this compound also showed tumor growth inhibition (TGI) against several types of tumors. Example compound II had greater than 100% TGI against U87MG, which indicated tumor shrinkage. The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Reference of 1-(Bromomethyl)-4-fluoro-2-iodobenzene

The Article related to thienopyridine preparation pharmaceutical composition, thienopyrimidine preparation vegf hgf receptor signaling inhibitor, thieno pyridine preparation vegf hgf receptor signaling inhibitor, pyridine thieno preparation treatment proliferative disease, pyrimidine thieno preparation treatment proliferative disease and other aspects.Reference of 1-(Bromomethyl)-4-fluoro-2-iodobenzene

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On December 21, 2018, Liu, Can; Zhu, Xianjin; Zhang, Pengxiang; Yang, Haijun; Zhu, Changjin; Fu, Hua published an article.Electric Literature of 70931-59-8 The title of the article was Axially Chiral Cyclic Diphosphine Ligand-Enabled Palladium-Catalyzed Intramolecular Asymmetric Hydroarylation. And the article contained the following:

In transition metal-catalyzed asym. synthesis, enantioselectivity strongly depends on the structures of chiral ligands, so the development of new chiral ligands is crucial. Here, an efficient and highly enantioselective palladium-catalyzed intramol. hydroarylation has been developed, and a new kind of N-heterocycles, 1H-pyrazolo[5,1-a]isoindol-2(8H)-ones containing a quaternary stereocenter, was prepared in high yields and excellent enantiomeric excess values. The reaction was effectively catalyzed by palladium-diphosphine complexes with numerous functional group tolerance, in which the newly developed axially chiral cyclic diphosphine ligands played key roles in the reactivity and enantioselectivity of the substrates. These cyclic diphosphine ligands with adjustable dihedral angles have wide application in asym. synthesis. The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Electric Literature of 70931-59-8

The Article related to pyrazoloisoindolone preparation enantioselective, iodobenzyl pyrazolone intramol hydroarylation palladium catalyst cyclic diphosphine ligand, axial chiral cyclic diphosphine ligand preparation, catalysis, chemistry, organic chemistry, stereochemistry and other aspects.Electric Literature of 70931-59-8

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com